Italy will have access to at
least 13.51% of the 300 million does of the highly promising new
Pfizer-BioNTech COVID vaccine reserved for the European Union,
European Commission sources said Tuesday.
The distribution of the vaccine, which has shown 90%
effectiveness in third stage trials, is proportionate to the
population of each member State, according to Eurostat data,
they said.
But Italy's allocation may be even higher, they said, depending
on possible opt-outs by other countries.
The EU is expected to get 200 million doses of the new vaccine
once it is approved, with an option for another 100 million.
ALL RIGHTS RESERVED © Copyright ANSA
